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INTRODUCTION
HIV continues to be an important public-health 
problem in India since its first detection in 1986. 
The national-level prevalence of HIV among adults 
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ABSTRACT
A community-based cross-sectional study was conducted among injecting drug-users (IDUs) of the north-
eastern states of India to understand the host genetic factors that confer resistance to HIV infection. The 
study aimed at assessing the existence and magnitude of genetic mutations of chemokine receptors, 
such as CCR2-64I, CCR-5 D-32, and SDF-1-3`A, that are known to confer resistance to HIV infection and 
progression of disease in some set-ups. In total, 711 IDUs from Manipur, Mizoram, Nagaland, and Megha-
laya were sampled for the study. The selected participants were interviewed to study their sociodemogra-
phy, risk behaviours, and risk perceptions after obtaining their verbal informed consent. The interview was 
followed by collection of about 5 mL of blood samples by an unlinked anonymous method for studying 
genetic mutation and HIV infection. All the blood samples were transported to and processed at the clini-
cal medicine laboratory of the National Institute of Cholera & Enteric Diseases, Kolkata, India. The genetic 
mutations were detected by polymerase chain reaction (PCR) and the restriction fragment length poly-
morphism (RFLP) assay techniques. The study revealed that 328 (46.1%) IDUs were aged 20-29 years, 305 
(42.9%) were aged 30-39 years, and only two (0.3%) were aged above 49 years. The rate of HIV seropositiv-
ity varied widely among the IDUs living in different northeastern states that ranged from 4.5% to 61%. 
There was not a single IDU with CCR5 homozygous mutation. Mutated genes of CCR2-64I and SDF-1-3’A 
were detected in the frequencies of 49% and 23% respectively in them. The rate of HIV seropositivity in 
IDUs having CCR2 mutant gene was 27% (n=94) and without mutation was 27% (n=98). Similarly, HIV se-
ropositivity in IDUs with and without SDF1 mutation was 28% (n=46) and 27% (n=146) respectively. Both 
the differences were not statistically significant. A CCR5 homozygous mutation is known to be the most 
prominent marker that confers resistance against HIV infection. The absence of CCR5 mutant gene in this 
population suggests that they do not have any additional protection against HIV infection. Analysis also 
revealed that, although mutation of CCR2 and SDF1 was present in this population, it did not confer any 
additional resistance against HIV. This indicates that the IDUs of northeastern India are not additionally 
protected against HIV infection through genetic mutation and are, therefore, vulnerable to acquire HIV 
infection due to high-risk behaviour and other related factors.
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in India is around 0.3%, which gives rise to an es-
timated 2-3.6 million HIV-infected people in the 
country (1). The genetic differences between indi-
viduals appear to be an essential factor towards pro-
tection against HIV infection despite indulgence in 
high-risk behaviour (2). The risk factors associated 
with the development of clinical disease and the   
life-span of HIV infection in individuals are less un-
derstood. 
Individuals with variants of the genes encoding 
the chemokine receptors—CCR2 and CCR5—and 
the ligand SDF1 have been shown to be resistant to 
HIV-1 infection and progression of disease (3-6). Of 
the three genetic markers, presence of homozygous 
CCR5 D-32 allele appears to be the most impor- Sarkar K et al. Host genetic mutation among injecting drug-users
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tant factor that confers resistance against HIV-1 
infection, and heterozygous mutation prevents 
the progression of disease (7). The natural resist-
ance to HIV-1 infection has been described by two 
mechanisms: one is termed ‘exposed-uninfected’ 
and the other one ‘long-term non-progressors’. In 
the former type, individuals are exposed repeat-
edly over a long period without any manifestations 
of HIV infection. Such individuals include com-
mercial sex workers, people having unprotected 
sex with infected partners, infants of HIV-positive 
mothers, IDUs, haemophiliacs, etc. The latter types 
of individuals carry HIV virus which either does 
not progress or progresses at a very slow rate. 
Homosexuals, IDUs, infants, or children usually 
fall in this group as described by Marmor et al. 
(8). Such facts have provided several options for 
research and development of more and more safe 
and effective drugs and vaccines to combat HIV in-
fection at a very early stage of its pathogenesis. 
Of all the northeastern states of India, Manipur 
in particular is contributing to the rapid spread of 
HIV-seropositive cases among IDUs (9). Although 
sharing  of  injecting  equipment  and  parapherna-
lia is the main mode of transmission among IDUs 
here, sexual transmission is also currently increas-
ing there (10). Transmission of HIV in local IDUs 
has always been viewed as an interaction between 
behavioural or cultural practices and presence of 
circulating HIV in the community. Influence of 
host factors, particularly genetic susceptibility, as 
mentioned above, has never been thought of and 
investigated in the said population. Hence, a study 
was conducted among IDUs of northeastern India 
to understand the existence and magnitude of ge-
netic variants encoding CCR5, CCR2, and SDF1 
and their relationships with the prevalence of HIV 
infection among them.
MATERIALS AND METHODS
This community-based cross-sectional study was   
conducted among 711 IDUs from four north-
eastern states: Manipur, Nagaland, Mizoram, and 
Meghalaya. Initially, the purpose of the study was 
explained to all the participants who were invited 
to participate voluntarily after obtaining their ver-
bal consent. Ethical clearance was obtained from 
the ethical committee of the National Institute of 
Cholera & Enteric Diseases (NICED) before initia-
tion of the study. Two experienced social workers 
interviewed the study participants using a field-
tested questionnaire to study their sociodemogra-
phy, risk behaviour, and risk perceptions about HIV 
infection. The interview was followed by collec-
tion of about 5 mL blood sample by an unlinked 
anonymous method for testing HIV and genetic 
mutation. All the samples were then transported 
to and processed at the clinical medicine labora-
tory of the NICED, a national AIDS reference 
laboratory. The genetic mutations were detected 
by polymerase chain reaction (PCR) and the re-
striction fragment length polymorphism (RFLP) 
assay techniques as described below. 
Primers for the amplification of CCR5 (FP: 5’ TTA 
AAA GCC AGG ACG GTC AC 3’ and RP: 5’ TGT 
AGG GAG CCC AGA AGA GA 3’), CCR2 (FP: 5’ 
TTG TGG GCA ACA TGA TGG 3’ and RP: 5’ CTG 
TGA ATA ATT TGC AGA TTG C 3’), and SDF1 (FP: 
5’ AAG GCT TCT CTC TGT GGG ATG 3’ and RP: 
5’ GAC AGT CGT GGA CAC ACA TGA T 3’) were 
custom-synthesized from Integrated DNA Tech-
nologies (IDT), Inc., USA. DNA was extracted from 
peripheral blood samples following the standard 
procedure. Peripheral blood mononuclear cells (PB-
MCs) were isolated from 100 to 200 µL of blood by 
pelleting down the cells at 1,000 rpm for five min-
utes. Red blood cells (RBCs) were lysed by re-sus-
pending the cell pellet in 500 µL of ACS-buffered 
saline, followed by incubation at room temperature 
for 3-4 minutes. Cell suspension was centrifuged at 
6,000 rpm for five minutes after the addition of 500 
µL of RPMI medium. The pellet containing PBMCs 
was washed with 500 µL of PBS and lysed by the 
addition of 500 µL of DNAZOL (invitrogen-USA). 
0.25 mL of 100% ethanol was then added to the   
lysate, and genomic DNA was spooled out with a 
pipette-tip and transferred to a fresh tube. DNA was 
washed twice with 0.8-1.0 mL of 75% ethanol and 
dissolved in 100 µL 8 mM NaOH. PCR amplifica-
tion of the genes under study was done in a 50-µL 
reaction containing 5 µL of 10xPCR buffer, 1 µL of 
dNTPs (2.5 mM stock), 0.4 µL of each primer (10 
μM stock), ng of genomic DNA, and 2.5 U of Taq 
DNA polymerase. For the amplification of CCR5, 
the reaction mixture was subjected to denaturation 
at 94 0C for five minutes, followed by 35 cycles of 
denaturation at 94 0C for 45 seconds, annealing 
at 62 0C for 30 seconds, and extension at 72 0C 
for one minute. For CCR2, initial denaturation was 
followed by 35 cycles of denaturation at 94 0C for 
one minute, annealing at 56 0C for 45 seconds, 
and extension at 72 0C for one minute. SDF-1 was 
also amplified for 35 cycles (denaturation at 94 0C 
for one minute, annealing at 50 0C for one minute, 
and extension at 72 0C for 1.30 minutes). A final 
primer extension at 72 0C for five minutes was al-
lowed in each case before the PCR was stopped. To 
analyze RFLP for SDF1-3’A, PCR products were di-
gested with MspI restriction enzyme at 37 0C for 16 
hours. RFLP for CCR2-64I was analyzed by digest-
ing the PCR product with BsaB1 for four hours at 
65 0C. The digested products were resolved in 3% 
agarose gel. All the data, including laboratory test    Sarkar K et al. Host genetic mutation among injecting drug-users
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results, were edited, entered, and analyzed using   
the Epi Info software (version 6.04). 
RESULTS
In total, 711 IDUs from four different northeastern 
states participated in the study. Figure 1 shows that 
Manipur had the highest number (n=306, 43%) of 
the study participants, followed by Mizoram 28% 
(n=199), Nagaland 21.9% (n=156), and Megha-
laya 7% (n=50). The HIV seropositivity was 62.1% 
(n=190), 4.5% (n=9), 11.5% (n=18), and 8% (n=4) 
in IDUs of Manipur, Mizoram, Nagaland, and Meg-
halaya respectively. 
Three hundred twenty-eight (46%) participants 
were aged 20-29 years, 305 (43%) were aged 30-39 
years, and 29 (4%) were aged 19 years or less. HIV 
seropositivity showed an increasing trend with the 
increase in age (Fig. 2). 
In terms of gender distribution, 94% (n=668) 
were male participants while 6% (n=43) were fe-
males. However, the rate of HIV seropositivity in   
female IDUs was more when compared with their 
male counterparts (females=65.1%; n=43 and 
males=28.9%; n=668). About half (51.2%; n=364) 
of them were unmarried, and 34.7% (n=247) were 
married. About 6.5% (n=46) were married but living 
separately without legal separation. The remaining 
3.7% (n=26) and 3.9% (n=28) were widows and 
divorcees respectively. Half (50.5%; n=359) of the 
study population was literate up to the level of 
secondary education, followed by primary educa-
tion (17.3%; n=123). About 36% (n=255) of the 
study subjects were unemployed. Other occupa-
tion-groups included service-holders, labourers, 
students, and businessmen in varying frequencies. 
Spasmoproxyvon was the most frequently-used 
substance (59%; n=419), followed by heroin (54%; 
n=384) and brown sugar (15%; n=109). 
A sizable number of the IDUs shared their inject-
ing equipment and paraphernalia. Transmission 
of HIV infection is known to be associated with 
sharing unsafe injection. Table 1 shows that 53.3% 
(n=379) of the participants shared their injecting 
equipment either always or frequently, and the rate 
of HIV seropositivity in them was 46.7% (n=177).  Sarkar K et al. Host genetic mutation among injecting drug-users
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Table 2. Relationship between mutated gene   
             and HIV status
Mutated gene
HIV- 
positive
HIV- 
negative
Total 
no.
CCR2
Wild type 98 (27) 262 360
Heterozygous 
mutated type 86 (26) 246 332
Homozygous 
mutated type 8 (44) 10 18
SDF1
Wild type 146 (27) 400 546
Heterozygous 
mutated type 42 (28) 106 148
Homozygous 
mutated type 4 (25) 12 16
Figures in parentheses indicate percentages
On the other hand, 46.6% (n=332) shared either 
occasionally or never, with an HIV-seropositivity 
rate of 13.2% (n=44). This difference was signifi-
cant as indicated by odds ratio (OR) of 5.7, with a 
95% confidence (CI) level of 3.8-8.5. 
In total, 237 (33.3%) of the IDUs shared drugs from 
common ampoules, with an HIV-seropositive rate 
of 63.3% (n=150), and 66.7% (n=474) did not have 
a similar history of sharing. The HIV-seropositive 
rate was 15% (n=71) in them. This difference was 
significant as indicated by OR of 9.7 and 95% CI 
level of 6.6-14.3. 62.3% (n=443) of the participants 
shared water for cleaning their syringes before 
injecting, and the rate of HIV seropositivity was 
42.7% (n=189) in them. On the contrary, 37.7%   
(n-268) did not share, and the rate of HIV sero 
positivity was 11.9% (n=32). This difference was 
significant indicated by OR of 5.4 and 95% CI level 
of 3.5-8.4. 21.4% (n=152) shared cotton to stop 
bleeding following injection with an HIV-seroposi-
tivity rate of 40.8% (n=62), 78.6% (n=559) did not 
share, and the rate of HIV seropositivity was 28.4% 
(n=159) in them. The difference was significant 
with OR of 1.7 and 95% CI level of 1.1-2.5 (Table 
1).
There was not a single IDU with CCR5 mutant 
gene. Distribution of the wild type, heterozygous 
and homozygous mutations in the CCR2 and SDF1 
genes in the study population are shown in Fig. 3.
Table 2 shows the seroprevalence of HIV among 
IDUs with and without the CCR2 and SDF1 mu-
tant genes. However, the difference was not signifi-
cant (p>0.05).
Table 1. Risk behaviour relating to sharing of injecting equipment/paraphernalia and HIV infection 
(n=711)
Particulars
Cases HIV-positive Odds ratio 
(95% CI)
p value
No. % No. %
Frequency of sharing
injecting equipment
  Always/frequently 379 53.3 177 46.7 5.7 (3.8-8.5) <0.05*
  Occasionally/never 332 46.6 44 13.2
Sharing of drugs from common 
ampoules
  Yes 237 33.3 150 63.3 9.79 (6.6-14.3) <0.05*
  No 474 66.7 71 15.0
Sharing of water for cleaning 
syringes before injection
  Yes 443 62.3 189 42.7 5.4 (3.5-8.4) <0.05*
  No 268 37.7 32 11.9
Sharing of used cotton to stop 
bleeding after injection
  Yes 152 21.4 62 40.8 1.73 (1.1-2.5) <0.05*
  No 559 78.6 159 28.4
*Significant
DISCUSSION
In total, 711 IDUs from four different northeastern 
states participated in the study. Forty-six percent 
(n=328) of the participants were aged 20-39 years. 
The youngest participants (4%; n=29) were aged 19 
years or less. HIV seropositivity was increasingly 
higher with increase in the age of IDUs (Fig. 2). 
This could be explained by the fact that the older 
IDUs have a longer duration of injection that could 
expose them to repeated unsafe injection practices.  Sarkar K et al. Host genetic mutation among injecting drug-users
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The unsafe injection practices are associated with 
transmission of blood-borne infection, including 
HIV, as evidenced by a number of studies (11,12).
The results of the study showed that the female 
IDUs (n=43) had a higher rate of HIV seropositivity 
compared to the male IDUs (n=668) as consistent 
with the findings of a study among IDUs in China 
(13). In the study community, most (90%) female 
IDUs were sex workers. This fact was also consistent 
with the findings of several other studies among 
female IDUs where the seroprevalence of HIV was 
more among female IDUs compared to males (14-
16). This could probably be explained by the dual 
route of entry of HIV in female IDUs, who were sex 
workers too. Unsafe sexual activity was a common 
risk behaviour encountered with them as observed 
in other studies (17,18).
Spasmoproxyvon was the highest consumable in- 
jectable drug in this part of the country, except 
parts of Manipur and Nagaland which are traversed 
by the national highway that acts as the heroin-
trafficking route (19,20). The national highway, 
which is also considered the heroin-trafficking 
route, starts from the India-Burma border to Ma-
nipur and passes to Nagaland after cutting across 
the capital city of Manipur, Imphal (21). Consump-
tion of drugs is associated with cultural acceptabil- 
ity, availability, and affordability (11). A study in   
Bangladesh observed that IDUs usually start addic-
tion with cannabis as the drug of choice and ends 
up with heroin (22). However, no such diversity in 
drug-use was observed in the present study. 
Unsafe injection-practices are frequently observed 
in most IDU communities. In this study, HIV sero-
positivity was observed in 47% (n=177) and 13% 
(n=44) of the IDUs with always or frequent shar-
ing and occasional or no sharing respectively (Table 
1). This difference was significant indicated by OR 
5.7. This implies that sharing is associated with 
higher transmission of HIV. Similarly, sharing of 
drugs from common ampoules, cleaning water, 
cotton, etc. were associated with higher transmis-
sion of HIV among sharers compared to non-
sharers. A similar observation was also made in a 
study of IDUs in a province in China (23). 
Several factors that  play an important role in the   
acquisition of HIV infection include viral load at 
entry-point (set point), the population density, 
risk behaviour and cultures of a society, immigra-
tion and mixing of population, rate of unemploy-
ment and poverty, availability, distribution, and 
consumption of drugs, and government policies 
(24). Moreover, about 90% of infected people are 
not aware that they are carrying the infection, and 
even if they did, anti-retroviral treatment is not 
an affordable option for them (18,25). Apart from 
these factors, host genetics plays an important role 
in viral entry giving rise to an epidemic. Results of 
a study showed that people who are homozygous 
to CCR5 mutation were protected from HIV-1 in-
fection, and on the other hand, heterozygous state 
renders partial protection against the infection 
(26). 
The HIV epidemic is spreading rapidly in Europe 
and North America from Asia and Africa due to 
mutation of HIV subtypes, intermixing of commu-
nities, intravenous drug-use, and commercial sex 
workers (27,28). Thus, genetic mutations need 
to be considered for the analysis of HIV-1 epidemic 
in a particular region, apart from risk factors and  Sarkar K et al. Host genetic mutation among injecting drug-users
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risk behaviours. The mutated gene of CCR5 chem-
okine co-receptor is a prominent genetic marker 
of HIV-1 resistance (7). In this study, none of the 
IDUs had CCR5-mutated gene which is consist-
ent with the finding of another study in diverse 
populations of Andhra Pradesh, South India (27) 
and also with the findings of studies in other parts 
of the world, such as Africa, America, Oceania, 
South-East Asia, and China (29). As in most parts 
of the world, the IDUs of northeastern India are 
not protected by any genetic mutation against HIV 
infection. 
The presence of CCR2 mutation in this study was 
much higher compared to other studies conducted 
on diverse populations of Andhra Pradesh, India 
(29) and in HIV patients of Kuwait (30). On match-
ing unsafe injection-practices, the rate of HIV sero-
positivity was observed to be almost equal in IDUs 
with and without CCR2 and SDF1 mutant genes. 
Since mutation in CCR2 and SDF1 genes slows the 
progression of HIV, IDUs with absence of these mu-
tated genes might have died earlier than those with 
mutations. Thus, the former may have been under-
represented in this study, leading to a bias in the 
results. Also, the study includes IDUs who are cur-
rently involved in injection-practices. The history 
of HIV seropositivity of the past IDUs should also be 
considered to get a true picture of the effect of host 
genetic mutation on HIV seroconversion and pro-
gression. So, the IDUs of northeastern states of India   
appear to have no additional protection against 
HIV-1 infection in absence of CCR5 mutation. Re-
garding the CCR2 and SDF1 genes, further cohort 
studies are required to understand whether the 
existing mutations in these genes confer any addi-
tional protection against progression of HIV-1.
The present study has explored the seroprevalence 
of HIV, injecting practices, and risk behaviours   
of current IDUs in four northeastern states of In- 
dia where injection-practices are widespread due to 
the easy availability of drugs. It also explores the 
existence and magnitude of genetic mutations of 
chemokine receptors in the IDUs of the northeast-
ern states to determine their genetic protection to 
HIV infection and progression. It has documented 
that unsafe injection-practices are widely prevalent 
in this part of India and shows significant contribu-
tion to the spread of HIV infection. The study also re-
vealed that the IDU population of this region is not 
additionally protected against HIV infection and its 
progression through genetic mutation of chemokine   
receptors,  such  as  CCR2-64I,  CCR-5  D-32,  and 
SDF-1-3’A. Unlike some parts of the world where 
such genetic mutation confers certain amount 
of protection to HIV infection despite high-
risk  behaviour, the IDUs in the northeastern 
states of India need to control unsafe injection 
and sexual practices to decrease the high preva-
lence of HIV in these states. Also, further in-depth 
cohort study needs to be conducted to under-
stand the effects of CCR2 and SDF1 mutation on 
the progression of HIV infection. Such studies   
can help us further understand the complex re-
lationship among HIV infection, progression of 
disease, and host genetic diversity.
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